Injectable GHK-CU and BPC157 were discussed for hair loss, but users did not notice significant hair changes. BPC157 was noted to help with shoulder issues.
Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.
The conversation is about the long-term safety trial results for pyrilutamide, which are expected soon. Treatments mentioned include Minoxidil, finasteride, and RU58841.
A user is using microneedling and rosemary/peppermint oil to treat hair loss, avoiding chemicals due to potential side effects. They have seen baby hairs growing after five weeks and plan to continue for a year.
Mixing Pyrilutamide powder with Minoxidil solution is being considered. The Minoxidil solution contains Minoxidil 5%, Azelaic acid 5%, ABN complex 0.8%, Retinol 0.025%, Caffeine 0.001%, and a delivery vehicle.
The user shared progress pictures and discussed using oral and topical Minoxidil, microneedling, recently starting finasteride, multivitamins, vitamin D3, vitamin K, tretinoin, and ketoconazole for hair loss. The conversation focuses on the effectiveness of these treatments.
Resveratrol may impair exercise benefits and isn't popular for heart health. Quercetin might reduce hair greying, while NMN is relatively new with limited information.
The user used 0.5 mL of 0.5 mg of Pyrilutamide for 60 days for hair loss, but didn't notice any hair growth. They shared their hormone panel results and are seeking advice on next steps.
The conversation discusses various treatments for hair loss, including high doses of dutasteride, oral minoxidil, RU58841, microneedling, ketoconazole shampoo, and other supplements like pumpkin seed oil and multivitamins. It also touches on more extreme measures like estrogen therapy and castration, with some users emphasizing the importance of overall health and nutrition.
Hair loss treatments discussed include promising Pyr available online and Verteporfin dosing after FUE for follicle regeneration, but no updates on SCUBE3.
The conversation discusses Peptonix microneedling, a copper peptide serum, as a potential hair loss treatment. Users compare it to finasteride and minoxidil, noting side effects and personal experiences with these treatments.
Akinfenrawr experienced negative side effects from oral finasteride and RU58841, and is seeking alternative hair loss treatments. They discuss various options, including raloxifene, oral dutasteride, liposomal finasteride, Breezula, Pyrilutamide, SM04554, and sulforaphane, but have concerns about efficacy, availability, and cost.
A 7-month progress report of using finasteride and minoxidil, as well as keto dieting and derma stamping; the discussion also touched on RU58841 and its potential side effects.
AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.
The user experienced side effects from finasteride and Nutrafol, opting for non-hormonal treatments like minoxidil, exercise, and a healthy lifestyle. Others discussed using Dutasteride, Biotin, and minoxidil with varying success and side effects.
The conversation discusses the high prices of hair loss treatments, specifically cb-03-01 and KY19382. It also mentions the use of Minoxidil, finasteride, and RU58841.
The conversation discusses expectations for the release of Breezula, a new hair loss treatment, and compares it to existing treatments like finasteride. Some believe Breezula could be a game-changer due to fewer side effects, while others await more permanent solutions like hair follicle cloning.
A user discusses switching from RU58841 to Pyrilutamide due to side effects like fatigue, brain fog, and elevated heart rate. They have used dutasteride, finasteride, and minoxidil, and are seeking safer alternatives.
The conversation is about seeking hairline regrowth results using RU58841, dermarolling, and Nizoral. The user cannot tolerate finasteride and finds minoxidil ineffective.
The conversation discusses adding either RU58841 or pyrilutamide to a hair loss treatment regimen that already includes oral dutasteride and oral minoxidil. RU58841 is considered the stronger anti-androgen but may have more side effects.
Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.
JXL082 is not the same as PP405, leading to a halt in sales and a plan to synthesize the real PP405. There is skepticism about the safety and effectiveness of JXL082 and PP405, with concerns about patent issues and the long-term impact on hair growth.
Actifollic selling Pyrilutamide as a treatment for hair loss, with people debating its efficacy compared to Minoxidil and Finasteride in combination with RU58841.
The conversation is about receiving a shipment of Koshine, also known as Kintor, which is an anti-androgen treatment for hair loss. The user is eager to try the KX-826 product and observe its effects and any side effects.
The user had been using Minoxidil and Dutasteride with micro-needling but experienced hair loss after switching Minoxidil brands. Their doctor prescribed oral Minoxidil and Tretinoin, but the pharmacist suggested isotretinoin might be a more cost-effective alternative.
Pyrilutamide's long-term stability is uncertain, with potential degradation after 8-9 months if not stored properly. It's recommended to use fresh batches and store them in a cool, dark place.
The conversation discusses the delay in the release of a new hair loss treatment, Pyrilutamide, and speculates on potential safety concerns as a reason for the delay. It also mentions GT20029 as another future treatment option, with a release at least five years away, and touches on the avoidance of research chemicals due to uncertainty about their authenticity.